Skip to main content
U.S. flag

An official website of the United States government

Biomarkers: Next generation CNS and biofluid markers (Milestone 9.B)

In Progress

Timeline Start - End

2014 - 2024

Research Implementation Area


Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures targeting a variety of disease processes (neuroinflammation, bioenergetic/metabolic compromise, oxidative stress, synaptic pathology) that can be used as research tools or developed into diagnostic, prognostic, theragnostic or target engagement biomarkers.

Success Criteria

  • Initiate synthesis and testing of CNS imaging ligands (PET/SPECT) for at least 12 novel, prioritized candidate targets.  Ensure that these reagents are made available as open source tools for target validation and predictive drug development.

  • Identify at least 6 multi-omic biomarker signatures (metabolomic, proteomic, cell-free RNAseq etc.) that can be quantitatively measured in peripheral fluids and have been validated across at least 3 diverse cohorts.

Summary of Key Accomplishments

NIA-supported researchers have developed five new PET ligands for five different, novel targets related to synaptic function, oxidative stress and neuroinflammation. These new ligands are being evaluated in animal models and in human brain samples. In addition, one of the main goals of the NIA-supported Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD) Consortium is to discover molecular biomarker signatures that can be measured in blood samples that reflect disease processes in the brain.

The key accomplishments summary is current as of March 2022. 

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health